17.73
-0.39(-2.15%)
Currency In USD
| Previous Close | 18.12 |
| Open | 18.28 |
| Day High | 18.92 |
| Day Low | 17.45 |
| 52-Week High | 19.93 |
| 52-Week Low | 7.75 |
| Volume | 82,596 |
| Average Volume | 28,122 |
| Market Cap | 135.41M |
| PE | -2.86 |
| EPS | -6.2 |
| Moving Average 50 Days | 14.31 |
| Moving Average 200 Days | 14.36 |
| Change | -0.39 |
If you invested $1000 in Assembly Biosciences, Inc. (ASMB) 10 years ago, it would be worth $77.97 as of July 02, 2025 at a share price of $17.73. Whereas If you bought $1000 worth of Assembly Biosciences, Inc. (ASMB) shares 5 years ago, it would be worth $63.74 as of July 02, 2025 at a share price of $17.73.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179
GlobeNewswire Inc.
Jun 30, 2025 12:00 PM GMT
– Study will evaluate safety and antiviral activity of ABI-1179 in participants with recurrent genital herpes – – ABI-1179 IND cleared to support study expansion to sites in United States – – Phase 1b studies for ABI-1179 and ABI-5366 running concurr
Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B
GlobeNewswire Inc.
Jun 25, 2025 12:00 PM GMT
– Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be observed in final 400 mg cohort – – Mean plasma HBV DNA reductions of 3.2 logs IU/mL over 28 days of treatment for 400 mg coh
Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference
GlobeNewswire Inc.
May 27, 2025 8:05 PM GMT
SOUTH SAN FRANCISCO, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that Jason Okazaki, chief executiv